Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

GeneOne Life Science, Inc.

진원생명과학011000KOSPISector: Pharma & Biotech
₩2,6700.00%Market cap ₩48.5BAs of Sep 1, 2026 close · updated once daily
Market cap
₩48.5B
#711 in KOSPI
Loss
PER not computable
1.19x
Sector median 1.61x
0.0%
Sector median 0.0%
Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Loading closing price history…
 
Low ₩2,670High ₩12,600
Latest close
Price change by period
1W
0.00%
1M
0.00%
3M
53.60%
1Y
75.90%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

10.0/100
How much debt does it carry relative to equity?
191.5%
Sector median 51.6%
Sector lowhighBottom 9.1% in sector
Can it cover what's due within a year?
36.1%
Sector median 191.7%
Sector lowhighBottom 3.4% in sector
How much of revenue becomes profit?
-191.1%
Sector median -2.4%
Sector lowhighBottom 20.3% in sector
How much did it earn on its own capital?
-126.8%
Sector median -4.5%
Sector lowhighBottom 7.1% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

25.5/100
How much did revenue grow in a year?
-35.5%
Sector median 6.4%
Sector lowhighBottom 7% in sector
Has it grown steadily over three years?
-22.1%
Sector median 4.9%
Sector lowhighBottom 9.6% in sector
Did core profits grow in a year?
-2.3%
Sector median 3.6%
Sector lowhighBottom 43.3% in sector
Are core profits higher than three years ago?
-9.9%
Sector median 3.5%
Sector lowhighBottom 42.2% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

30.2/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 3% in sector
Is the price expensive relative to book value?
1.19x
Sector median 1.61x
Sector lowhighTop 42.7% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
209,464 shares (0.2% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 1 met · 8 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩51.9B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩16.5B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-32.1% → -34.3%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩16.5B vs -₩51.9B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
43.4% → 65.7%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
67.4% → 36.1%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
80,039,035 → 85,409,936
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
-120.5% → -191.1%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.24x → 0.15x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026F

Methodology version change (v2.0 applied)

Jul 15, 2026FVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 6,224,066 new shares, equal to 34.2% of shares outstanding before the increase (filed 2026-08-24). View filing ↗

Private CB/BW issuance resolutions (past 36 months)

2 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2026-04-28). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

2 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2026-04-28). View filing ↗

CEO (representative executive officer) change filings (past 36 months)

3 CEO (representative executive officer) change filings were submitted in the past 36 months (latest filing 2026-08-06). View filing ↗

Largest-shareholder changes (past 36 months)

The largest shareholder changed 6 times in the past 36 months (latest change 2025-08-29, per annual report).

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Paid-in capital increaseAug 24, 2026Source ↗
Periodic report filedAug 14, 2026Source ↗
CEO changeAug 6, 2026Source ↗
CEO changeJun 12, 2026Source ↗
Capital reductionMay 26, 2026Source ↗

View in the filings calendar →